RMP / REMS

Risk Management Plan / Risk Evaluation and Mitigation Strategy

An EU Risk Management Plan is built around the safety specification: what is known (identified risks), what is suspected (potential risks), and what is simply not yet known (missing information — for example use in pregnancy, in children, or in severe renal impairment). Each of those drives either additional pharmacovigilance activity to characterise it, or a risk-minimisation measure to control it, proportionate to the risk.

Risk minimisation splits into routine and additional. Routine measures are the ordinary tools — the SmPC and package leaflet, labelling, pack size, legal supply status. Additional measures are used only when routine ones are insufficient: educational materials, controlled access programmes, pregnancy prevention programmes, patient cards. Regulators expect you to justify why additional measures are needed and to measure whether they actually work.

The US REMS is the analogous instrument but a distinct legal construct under the FD&C Act, imposed by FDA where needed to ensure benefits outweigh risks. Its elements range from a Medication Guide or communication plan up to Elements To Assure Safe Use — restricted prescribing, dispensing, or monitoring. Both instruments are living: they are updated as the safety profile evolves and their effectiveness must be assessed, not assumed.

• —EU RMP structure: safety specification → pharmacovigilance plan → risk-minimisation measures.
• —Safety specification covers identified risks, potential risks, and missing information.
• —Routine risk minimisation (SmPC, leaflet, labelling, pack size, legal status) before additional measures.
• —Additional measures (educational material, controlled access, pregnancy prevention) require justification and effectiveness measurement.
• —US REMS is the analogous instrument under the FD&C Act, up to Elements To Assure Safe Use.
• —Both are living documents — updated as the benefit-risk profile changes.

EU: EMA GVP Module V (Risk Management Systems) and Commission Implementing Regulation (EU) No 520/2012; US: Federal Food, Drug, and Cosmetic Act §505-1 (REMS, introduced by FDAAA 2007).